FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evan Kharasch

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Area Under Curve

Anatomy

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Jeremiah J Morrissey; Evan D Kharasch
The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma.
Sarah Gadel; Amanda Crafford; Karen Regina; Evan D Kharasch
Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Evan D Kharasch; Kristi Stubbert
Role of cytochrome P4502B6 in methadone metabolism and clearance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evan Kharasch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jeremiah J Morrissey; Evan D Kharasch
The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma.
The Journal of urology 2013;189(5):1913-20.
2013: Sarah Gadel; Amanda Crafford; Karen Regina; Evan D Kharasch
Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(4):709-13.
2013: Evan D Kharasch; Kristi Stubbert
Role of cytochrome P4502B6 in methadone metabolism and clearance.
Journal of clinical pharmacology 2013;53(3):305-13.
2012: Limei Tian; Naveen Gandra; Ramesh Kattumenu; Evan D Kharasch; Jeremiah J Morrissey; Srikanth Singamaneni
Bioplasmonic paper as a platform for detection of kidney cancer biomarkers.
Analytical chemistry 2012;84(22):9928-34.
2012: Sarah M Brown; Scott D Campbell; Amanda Crafford; Michael J Holtzman; Karen J Regina; Evan D Kharasch
P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.
The Journal of pharmacology and experimental therapeutics 2012;343(1):53-61.
2012: Evan D Kharasch; A London; K Stubbert; Dale Whittington; P S Bedynek; S Campbell; A Crafford; D Ensign; Christine Hoffer; T Kim
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics 2012;91(4):673-84.
2012: Evan D Kharasch
Getting oil and water to mix.
Anesthesiology 2012;116(3):504-6.
2012: Brian J Kirby; Kenneth E Thummel; Ann C Collier; Evan D Kharasch; Dale Whittington; Jashvant D Unadkat
Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(3):610-6.
2012: Evan D Kharasch; Alysa Walker; Pamela Sheffels Bedynek; Christine Hoffer; Dale Whittington
Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
Anesthesiology 2012;116(2):432-47.
2011: Anshuman Sharma; Danielle Tallchief; Jane Blood; Thomas Kim; Amy London; Evan D Kharasch
Perioperative pharmacokinetics of methadone in adolescents.
Anesthesiology 2011;115(6):1153-61.
2011: Brian J Kirby; Kenneth E Thummel; Dale Whittington; Ann C Collier; Pankaj Desai; Vaishali Dixit; Evan D Kharasch; Jashvant D Unadkat
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(12):2329-37.
2011: Peter Nagele; Anshuman Sharma; Danielle Tallchief; Jane Blood; Evan D Kharasch
Nitrous oxide anesthesia and plasma homocysteine in adolescents.
Anesthesia and analgesia 2011;113(4):843-8.
2011: Joseph Bloom; Alison Goate; Anthony L Hinrichs; Evan D Kharasch; Linda B von Weymarn; Jen C Wang; Laura J Bierut; Sharon E Murphy
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Pharmacogenetics and genomics 2011;21(7):403-16.
2011: Evan D Kharasch; T Kim; A London; A Francis; K Frey; J Blood
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Clinical pharmacology and therapeutics 2011;90(1):100-8.
2011: Todd J Schwedt; Karen Frey; Robert W Gereau; Evan D Kharasch
Headache outcomes following treatment of unruptured intracranial aneurysms: a prospective analysis.
Cephalalgia : an international journal of headache 2011;31(10):1082-9.
2011: Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(6):1070-8.
2011: Thomas Kim; Amy London; Evan D Kharasch
Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2011;55(3):487-93.
2011: Jinda Fan; Sarah M Brown; Zhude Tu; Evan D Kharasch
Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.
Bioconjugate chemistry 2011;22(4):752-8.
2011: Evan D Kharasch; Suwanna Vangveravong; N Buck; A London; T Kim; J Blood; Robert H Mach
Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Clinical pharmacology and therapeutics 2011;89(4):562-70.
2011: Jinda Fan; Konrad Meissner; Gregory G Gaehle; Shihong Li; Evan D Kharasch; Robert H Mach; Zhude Tu
Automated radiosynthesis of [11C]morphine for clinical investigation.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2011;69(2):431-5.
2011: Jeremiah J Morrissey; Matthew C Lambert; Amy N London; Evan D Kharasch
Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma.
American journal of nephrology 2011;34(5):391-8.
2011: Evan D Kharasch
Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?
Anesthesia and analgesia 2011;112(1):13-6.
2010: Melanie S Joy; Reginald F Frye; Kristi Stubbert; Kim R Brouwer; Ronald J Falk; Evan D Kharasch
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
Journal of clinical pharmacology 2010;50(6):714-20.
2010: Jeremiah J Morrissey; Amy N London; Jingqin Luo; Evan D Kharasch
Urinary biomarkers for the early diagnosis of kidney cancer.
Mayo Clinic proceedings. Mayo Clinic 2010;85(5):413-21.
2009: Jacqueline E Pickrell; Kazuo Hosaka; Douglass L Jackson; Masahiro Heima; Evan D Kharasch; Peter Milgrom
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Journal of clinical psychopharmacology 2009;29(5):426-31.
2009: Michael C Montana; Laura F Cavallone; Kristi K Stubbert; Andrei D Stefanescu; Evan D Kharasch; Robert W Gereau
The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.
The Journal of pharmacology and experimental therapeutics 2009;330(3):834-43.
2009: William L Lanier; Evan D Kharasch
Contemporary clinical opioid use: opportunities and challenges.
Mayo Clinic proceedings. Mayo Clinic 2009;84(7):572-5.
2009: Evan D Kharasch; Gowdahalli N Subbarao; Keith Richard Cromack; Dennis A Stephens; Mario Saltarelli
Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers.
Anesthesia and analgesia 2009;108(6):1796-802.
2009: Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.
Drug and alcohol dependence 2009;101(3):158-68.
2009: Evan D Kharasch; Christine Hoffer; Dale Whittington; Alysa Walker; Pamela Sheffels Bedynek
Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.
Anesthesiology 2009;110(3):660-72.
2008: Evan D Kharasch; P S Bedynek; Alysa Walker; Dale Whittington; Christine Hoffer
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Clinical pharmacology and therapeutics 2008;84(4):506-12.
2008: Evan D Kharasch; P S Bedynek; S Park; Dale Whittington; Alysa Walker; Christine Hoffer
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
Clinical pharmacology and therapeutics 2008;84(4):497-505.
2008: Evan D Kharasch
Mutations in a molecule: the virtues of antagonism.
Mayo Clinic proceedings. Mayo Clinic 2008;83(10):1083-6.
2008: Jerrold Lerman; Evan D Kharasch; James Eisenach; Mark A Warner; Vesna Jevtovic-Todorovic; Piyush M Patel; Lena S Sun
Journal-related and other special activities at the 2008 American Society of Anesthesiologists Annual Meeting.
Anesthesiology 2008;109(3):365.
2008: Evan D Kharasch
Adverse drug reactions with halogenated anesthetics.
Clinical pharmacology and therapeutics 2008;84(1):158-62.
2008: Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Molecular characterization of CYP2B6 substrates.
Current drug metabolism 2008;9(5):363-73.
2008: Rebecka Coles; Evan D Kharasch
Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Pharmaceutical research 2008;25(6):1405-11.
2008: Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Antimicrobial agents and chemotherapy 2008;52(5):1663-9.
2008: Evan D Kharasch; Darain Mitchell; Rebecka Coles
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Journal of clinical pharmacology 2008;48(4):464-74.
2008: Rheem A Totah; Pamela Sheffels; Toni Roberts; Dale Whittington; Kenneth E Thummel; Evan D Kharasch
Role of CYP2B6 in stereoselective human methadone metabolism.
Anesthesiology 2008;108(3):363-74.
2008: I E Templeton; Kenneth E Thummel; Evan D Kharasch; Kent L Kunze; Christine Hoffer; Wendel L Nelson; Nina Isoherranen
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Clinical pharmacology and therapeutics 2008;83(1):77-85.
2007: Evan D Kharasch; Alysa Walker; Nina Isoherranen; Christine Hoffer; Pamela Sheffels; Kenneth E Thummel; Dale Whittington; D Ensign
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Clinical pharmacology and therapeutics 2007;82(4):410-26.
2007: Rebecka Coles; Evan D Kharasch
Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;857(1):67-75.
2007: Dennis E Feierman; Giuseppe Trunfio; Anand Morankar; Evan D Kharasch
More than polymorphism.
Anesthesia and analgesia 2007;104(6):1605; author reply 1605-6.
2007: Evan D Kharasch
Every breath you take, we'll be watching you.
Anesthesiology 2007;106(4):652-4.
2007: Rheem A Totah; Kyle E Allen; Pamela Sheffels; Dale Whittington; Evan D Kharasch
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
The Journal of pharmacology and experimental therapeutics 2007;321(1):389-99.
2006: R Douglas Bruce; Elinore F McCance-Katz; Evan D Kharasch; David E Moody; Gene D Morse
Pharmacokinetic interactions between buprenorphine and antiretroviral medications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43 Suppl 4():S216-23.
2006: Brian Kirby; Evan D Kharasch; Kenneth T Thummel; Vishal S Narang; Christine Hoffer; Jashvant D Unadkat
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Journal of clinical pharmacology 2006;46(11):1313-9.
2006: Evan D Kharasch; Jesara L Schroeder; H Denny Liggitt; Dustin Ensign; Dale Whittington
New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites.
Anesthesiology 2006;105(4):737-45.
2006: Evan D Kharasch; Jesara L Schroeder; H Denny Liggitt; Sang B Park; Dale Whittington; Pamela Sheffels
New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1): Identification of the nephrotoxic metabolic pathway.
Anesthesiology 2006;105(4):726-36.
2006: Bojan Lalovic; Evan D Kharasch; Christine Hoffer; Linda Risler; Lee-Yuan Liu-Chen; Danny D Shen
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Clinical pharmacology and therapeutics 2006;79(5):461-79.
2006: Kent L Kunze; Wendel L Nelson; Evan D Kharasch; Kenneth E Thummel; Nina Isoherranen
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):583-90.
2006: Evan D Kharasch; Jesara L Schroeder; Theo Bammler; Richard P Beyer; Sengkeo Srinouanprachanh
Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats.
Toxicological sciences : an official journal of the Society of Toxicology 2006;90(2):419-31.
2006: Douglass L Jackson; Peter Milgrom; Gail A Heacox; Evan D Kharasch
Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Journal of clinical psychopharmacology 2006;26(1):4-8.
2005: Evan D Kharasch; Jesara L Schroeder; Pamela Sheffels; H Denny Liggitt
Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
Anesthesiology 2005;103(6):1183-8.
2005: Harshvardhan N Chaobal; Evan D Kharasch
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Clinical pharmacology and therapeutics 2005;78(5):529-39.
2005: Evan D Kharasch; Alysa Walker; Christine Hoffer; Pamela Sheffels
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Journal of clinical pharmacology 2005;45(10):1187-97.
2005: Evan D Kharasch; Kenneth E Thummel; Paul B Watkins
CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.
Molecular interventions 2005;5(3):151-3.
2005: Theresa Mariero Klees; Pamela Sheffels; Kenneth E Thummel; Evan D Kharasch
Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Anesthesiology 2005;102(3):550-6.
2005: Theresa Mariero Klees; Pamela Sheffels; Ola Dale; Evan D Kharasch
Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(3):303-11.
2005: Gregory Dembo; Sang B Park; Evan D Kharasch
Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.
Anesthesiology 2005;102(2):409-15.
2005: Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pamela Sheffels; Bojan Lalovic
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Clinical pharmacokinetics 2005;44(7):731-51.
2005: Evan D Kharasch; Alysa Walker; Christine Hoffer; Pamela Sheffels
Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Journal of clinical pharmacology 2005;45(1):79-88.
2004: Evan D Kharasch; Alysa Walker; Christine Hoffer; Pamela Sheffels
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Clinical pharmacology and therapeutics 2004;76(5):452-66.
2004: Yang Dai; Kazunori Iwanaga; Yvonne S Lin; Mary F Hebert; Connie L Davis; Weili Huang; Evan D Kharasch; Kenneth E Thummel
In vitro metabolism of cyclosporine A by human kidney CYP3A5.
Biochemical pharmacology 2004;68(9):1889-902.
2004: Dale Whittington; Pamela Sheffels; Evan D Kharasch
Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(2):313-21.
2004: Pamela Sheffels; Jesara L Schroeder; T Gul Altuntas; H Denny Liggitt; Evan D Kharasch
Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
Chemical research in toxicology 2004;17(9):1177-89.
2004: Evan D Kharasch; Christine Hoffer; Dale Whittington; Pamela Sheffels
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Clinical pharmacology and therapeutics 2004;76(3):250-69.
2004: Evan D Kharasch; Christine Hoffer; Dale Whittington
Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate.
Anesthesiology 2004;101(3):738-43.
2004: Evan D Kharasch; Dale Whittington; Christine Hoffer
Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Anesthesiology 2004;101(3):729-37.
2004: Ola Dale; Pamela Sheffels; Evan D Kharasch
Bioavailabilities of rectal and oral methadone in healthy subjects.
British journal of clinical pharmacology 2004;58(2):156-62.
2004: Evan D Kharasch; Michael Mulroy; Jeffrey L Apfelbaum
Toxicity during tumescent lipoplasty: a commentary.
Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery 2004;24(4):311-3.
2004: Evan D Kharasch; Christine Hoffer; Dale Whittington
The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
British journal of clinical pharmacology 2004;57(5):600-10.
2004: T Gul Altuntas; Sang B Park; Evan D Kharasch
Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).
Chemical research in toxicology 2004;17(3):435-45.
2004: Evan D Kharasch; Christine Hoffer; T Gul Altuntas; Dale Whittington
Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Journal of clinical pharmacology 2004;44(3):224-33.
2004: Evan D Kharasch
Perioperative COX-2 inhibitors: knowledge and challenges.
Anesthesia and analgesia 2004;98(1):1-3.
2003: Evan D Kharasch; Christine Hoffer; Dale Whittington; Pamela Sheffels
Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Clinical pharmacology and therapeutics 2003;74(6):543-54.
2003: Dermot R Fitzgibbon; Donna Morgan; Deanna Dockter; Chris Barry; Evan D Kharasch
Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients.
Pain 2003;106(3):309-15.
2003: T Gul Altuntas; Richard A Zager; Evan D Kharasch
Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
Toxicology and applied pharmacology 2003;193(1):55-65.
2003: Dale Whittington; Evan D Kharasch
Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):95-103.
2003: Maurice G Emery; Jeannine M Fisher; Jenny Y Chien; Evan D Kharasch; E Patchen Dellinger; Kris V Kowdley; Kenneth E Thummel
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) 2003;38(2):428-35.
2003: DK Spracklin; M E Emery; Kenneth E Thummel; Evan D Kharasch
Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats.
Acta anaesthesiologica Scandinavica 2003;47(6):765-70.
2003: David R McIlroy; Evan D Kharasch
Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia.
Anesthesia and analgesia 2003;96(6):1572-7, table of contents.
2003: Caiping Yao; Kent L Kunze; William F Trager; Evan D Kharasch; René H Levy
Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(5):565-71.
2003: Andra E Ibrahim; Jennifer Feldman; Aziz Karim; Evan D Kharasch
Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Anesthesiology 2003;98(4):853-61.
2003: Evan D Kharasch; Christine Hoffer; Alysa Walker; Pamela Sheffels
Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Clinical pharmacology and therapeutics 2003;73(3):199-208.
2002: Ola Dale; Christine Hoffer; Pamela Sheffels; Evan D Kharasch
Disposition of nasal, intravenous, and oral methadone in healthy volunteers.
Clinical pharmacology and therapeutics 2002;72(5):536-45.
2002: Peter Conzen; Evan D Kharasch; Stephan F A Czerner; Alan A Artru; Florian M Reichle; Piotr Michalowski; G Alec Rooke; Branko M Weiss; Thomas J Ebert
Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
Anesthesiology 2002;97(3):578-84.
2002: Andra Ibrahim; Aziz Karim; Jennifer Feldman; Evan D Kharasch
The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Anesthesia and analgesia 2002;95(3):667-73, table of contents.
2002: Ola Dale; R Hjortkjaer; Evan D Kharasch
Nasal administration of opioids for pain management in adults.
Acta anaesthesiologica Scandinavica 2002;46(7):759-70.
2002: T Gul Altuntas; Evan D Kharasch
Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(2):148-54.
2002: Evan D Kharasch; Karen M Powers; Alan A Artru
Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo.
Anesthesiology 2002;96(1):173-82.
2002: Andra Ibrahim; Sang Park; Jennifer Feldman; Aziz Karim; Evan D Kharasch
Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.
Anesthesiology 2002;96(1):88-95.
2001: S Phimmasone; Evan D Kharasch
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Clinical pharmacology and therapeutics 2001;70(6):505-17.
2001: T Gul Altuntas; Evan D Kharasch
Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
Toxicology and applied pharmacology 2001;177(2):85-93.
2001: Yvonne S Lin; Graham F Lockwood; Martin A Graham; W R Brian; C M Loi; M R Dobrinska; Danny D Shen; Paul B Watkins; G R Wilkinson; Evan D Kharasch; Kenneth E Thummel
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
Pharmacogenetics 2001;11(9):781-91.
2001: Evan D Kharasch; EJ Frink; Alan A Artru; Piotr Michalowski; G Alec Rooke; WM Nogami
Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function.
Anesthesia and analgesia 2001;93(6):1511-20, table of contents.
2001: Kenneth E Thummel; C Brimer; Kazuto Yasuda; J Thottassery; T Senn; Y Lin; H Ishizuka; Evan D Kharasch; John D Schuetz; Erin G Schuetz
Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3.
Molecular pharmacology 2001;60(6):1399-406.
2001: Caiping Yao; Kent L Kunze; Evan D Kharasch; Y Wang; William F Trager; I Ragueneau; René H Levy
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
Clinical pharmacology and therapeutics 2001;70(5):415-24.
2001: Andra E Ibrahim; JK Taraday; Evan D Kharasch
Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol.
Anesthesiology 2001;95(5):1151-9.
2001: Jorge L Castillo; Peter Milgrom; Evan D Kharasch; K Izutsu; M Fey
Evaluation of fluoride release from commercially available fluoride varnishes.
Journal of the American Dental Association (1939) 2001;132(10):1389-92; quiz 1459-60.
2001: Y Oda; Evan D Kharasch
Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.
The Journal of pharmacology and experimental therapeutics 2001;298(3):1021-32.
2001: Y Minoda; Evan D Kharasch
Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6).
Anesthesiology 2001;95(2):509-14.
2001: C M Tweedy; Peter Milgrom; Evan D Kharasch; Tarja Kaakko; M Spieker; Susan E Coldwell
Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients.
Journal of clinical psychopharmacology 2001;21(3):268-72.
2001: Andra E Ibrahim; M M Ghoneim; Evan D Kharasch; R H Epstein; Scott B Groudine; T J Ebert; W B Binstock; B K Philip
Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam.
Anesthesiology 2001;94(1):87-94.
2000: P T Manyike; Evan D Kharasch; Thomas F Kalhorn; John T Slattery
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation.
Clinical pharmacology and therapeutics 2000;67(3):275-82.
2000: Evan D Kharasch; DC Hankins; K Fenstamaker; K Cox
Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4.
European journal of clinical pharmacology 2000;55(11-12):853-9.
2000: Evan D Kharasch; DC Hankins; JK Taraday
Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(1):28-33.
1999: Evan D Kharasch; C Jubert
Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
Anesthesiology 1999;91(5):1267-78.
1999: Connie L Davis; Annamaria T Kausz; Richard A Zager; Evan D Kharasch; R P Cochran
Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels.
Journal of the American Society of Nephrology : JASN 1999;10(11):2396-402.
1999: Evan D Kharasch; C Jubert; DK Spracklin; G M Hoffman
Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
Toxicology and applied pharmacology 1999;160(1):49-59.
1999: M G Emery; C Jubert; Kenneth E Thummel; Evan D Kharasch
Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
The Journal of pharmacology and experimental therapeutics 1999;291(1):213-9.
1999: Evan D Kharasch; C Jubert; T Senn; T A Bowdle; Kenneth E Thummel
Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
Journal of clinical pharmacology 1999;39(7):664-9.
1999: Evan D Kharasch; DC Hankins; C Jubert; Kenneth E Thummel; JK Taraday
Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(6):717-23.
1999: Scott B Groudine; R J Fragen; Evan D Kharasch; T S Eisenman; EJ Frink; S McConnell
Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane.
Journal of clinical anesthesia 1999;11(3):201-7.
1999: Evan D Kharasch; DC Hankins; K Cox
Clinical isoflurane metabolism by cytochrome P450 2E1.
Anesthesiology 1999;90(3):766-71.
1999: Evan D Kharasch; DS Mautz; T Senn; G Lentz; K Cox
Menstrual cycle variability in midazolam pharmacokinetics.
Journal of clinical pharmacology 1999;39(3):275-80.
1998: Evan D Kharasch
[Compound A: toxicology and clinical relevance].
Der Anaesthesist 1998;47 Suppl 1():S7-10.
1998: Allen D Radant; T Andrew Bowdle; Deborah S Cowley; Evan D Kharasch; Peter P Roy-Byrne
Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(5):434-44.
1998: PJ Baxter; Kyle J Garton; Evan D Kharasch
Mechanistic aspects of carbon monoxide formation from volatile anesthetics.
Anesthesiology 1998;89(4):929-41.
1998: Evan D Kharasch; DC Hankins; PJ Baxter; Kenneth E Thummel
Single-dose disulfiram does not inhibit CYP2A6 activity.
Clinical pharmacology and therapeutics 1998;64(1):39-45.
1998: Evan D Kharasch; G M Hoffman; David R Thorning; DC Hankins; C G Kilty
Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
Anesthesiology 1998;88(6):1624-33.
1998: DK Spracklin; Evan D Kharasch
Human halothane reduction in vitro by cytochrome P450 2A6 and 3A4: identification of low and high KM isoforms.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(6):605-7.
1998: Thomas J Ebert; EJ Frink; Evan D Kharasch
Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
Anesthesiology 1998;88(3):601-10.
1998: RB Palmer; DS Mautz; K Cox; Evan D Kharasch
Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism.
The American journal of emergency medicine 1998;16(2):170-2.
1998: KM Lochhead; Evan D Kharasch; Richard A Zager
Anesthetic effects on the glycerol model of rhabdomyolysis-induced acute renal failure in rats.
Journal of the American Society of Nephrology : JASN 1998;9(2):305-9.
1998: Susan E Coldwell; E Kaufman; Peter Milgrom; Evan D Kharasch; P Chen; DS Mautz; Douglas S Ramsay
Acute tolerance and reversal of the motor control effects of midazolam.
Pharmacology, biochemistry, and behavior 1998;59(2):537-45.
1998: T Andrew Bowdle; Allen D Radant; Deborah S Cowley; Evan D Kharasch; R J Strassman; Peter P Roy-Byrne
Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.
Anesthesiology 1998;88(1):82-8.
1997: Peter R Freund; T Andrew Bowdle; Karen L Posner; Evan D Kharasch; V D Burkhart
Cost-effective reduction of neuromuscular-blocking drug expenditures.
Anesthesiology 1997;87(5):1044-9.
1997: Thomas J Ebert; Evan D Kharasch; G Alec Rooke; A Shroff; M Muzi
Myocardial ischemia and adverse cardiac outcomes in cardiac patients undergoing noncardiac surgery with sevoflurane and isoflurane. Sevoflurane Ischemia Study Group.
Anesthesia and analgesia 1997;85(5):993-9.
1997: RB Labroo; Mary F Paine; Kenneth E Thummel; Evan D Kharasch
Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(9):1072-80.
1997: T Andrew Bowdle; LB Ready; Evan D Kharasch; W W Nichols; K Cox
Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery.
European journal of anaesthesiology 1997;14(4):374-9.
1997: Evan D Kharasch; M Russell; DS Mautz; Kenneth E Thummel; K L Kunze; A Bowdle; K Cox
The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Anesthesiology 1997;87(1):36-50.
1997: Evan D Kharasch; M Russell; Kyle J Garton; G Lentz; T A Bowdle; K Cox
Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Anesthesiology 1997;87(1):26-35.
1997: Evan D Kharasch; EJ Frink; Richard A Zager; T Andrew Bowdle; Alan A Artru; WM Nogami
Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
Anesthesiology 1997;86(6):1238-53.
1997: KM Lochhead; Evan D Kharasch; Richard A Zager
Spectrum and subcellular determinants of fluorinated anesthetic-mediated proximal tubular injury.
The American journal of pathology 1997;150(6):2209-21.
1997: Helen W Karl; Peter Milgrom; Peter K Domoto; Evan D Kharasch; Susan E Coldwell; Philip Weinstein; Brian G Leroux; K Awamura; DS Mautz
Pharmacokinetics of oral triazolam in children.
Journal of clinical psychopharmacology 1997;17(3):169-72.
1997: DC Hankins; Evan D Kharasch
Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;692(2):413-8.
1997: PJ Baxter; Evan D Kharasch
Rehydration of desiccated Baralyme prevents carbon monoxide formation from desflurane in an anesthesia machine.
Anesthesiology 1997;86(5):1061-5.
1997: DK Spracklin; DC Hankins; Jeannine M Fisher; Kenneth E Thummel; Evan D Kharasch
Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro.
The Journal of pharmacology and experimental therapeutics 1997;281(1):400-11.
1997: Evan D Kharasch
Pharmacovigilance and safety aspects of sevoflurane.
Acta anaesthesiologica Scandinavica. Supplementum 1997;111():146-8.
1997: Evan D Kharasch; David R Thorning; Kyle J Garton; DC Hankins; C G Kilty
Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
Anesthesiology 1997;86(1):160-71.
1996: DK Spracklin; Kenneth E Thummel; Evan D Kharasch
Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(9):976-83.
1996: Evan D Kharasch; M Sivarajan
Gastroesophageal perforation after intraoperative transesophageal echocardiography.
Anesthesiology 1996;85(2):426-8.
1996: DK Spracklin; Evan D Kharasch
Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
Chemical research in toxicology 1996;9(4):696-702.
1996: Evan D Kharasch; DC Hankins
P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):649-54.
1996: G Alec Rooke; T Ebert; M Muzi; Evan D Kharasch
The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group.
Anesthesia and analgesia 1996;82(6):1159-65.
1996: Evan D Kharasch; DC Hankins; DS Mautz; Kenneth E Thummel
Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis.
Lancet 1996;347(9012):1367-71.
1996: L Jin; Margaret R Davis; Evan D Kharasch; George A Doss; Thomas A Baillie
Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane.
Chemical research in toxicology 1996;9(2):555-61.
1996: A K Mitra; Kenneth E Thummel; Thomas F Kalhorn; Evan D Kharasch; Jashvant D Unadkat; John T Slattery
Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers.
Clinical pharmacology and therapeutics 1996;59(3):332-40.
1996: Evan D Kharasch
Metabolism and toxicity of the new anesthetic agents.
Acta anaesthesiologica Belgica 1996;47(1):7-14.
1995: Kyle J Garton; P Yuen; J Meinwald; Kenneth E Thummel; Evan D Kharasch
Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(12):1426-30.
1995: Evan D Kharasch
Biotransformation of sevoflurane.
Anesthesia and analgesia 1995;81(6 Suppl):S27-38.
1995: A K Mitra; Kenneth E Thummel; Thomas F Kalhorn; Evan D Kharasch; Jashvant D Unadkat; John T Slattery
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.
Clinical pharmacology and therapeutics 1995;58(5):556-66.
1995: Evan D Kharasch; A S Armstrong; K Gunn; Alan A Artru; K Cox; M D Karol
Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation.
Anesthesiology 1995;82(6):1379-88.
1995: Evan D Kharasch; M D Karol; C Lanni; Ronald Sawchuk
Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics.
Anesthesiology 1995;82(6):1369-78.
1995: L Jin; Thomas A Baillie; Margaret R Davis; Evan D Kharasch
Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
Biochemical and biophysical research communications 1995;210(2):498-506.
1995: R B Labroo; Kenneth E Thummel; Kent L Kunze; T Podoll; William F Trager; Evan D Kharasch
Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(4):490-6.
1995: Evan D Kharasch; DC Hankins; Kenneth E Thummel
Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity.
Anesthesiology 1995;82(3):689-99.
1994: R Labroo; Evan D Kharasch
Gas chromatographic-mass spectrometric analysis of alfentanil metabolites. Application to human liver microsomal alfentanil biotransformation.
Journal of chromatography. B, Biomedical applications 1994;660(1):85-94.
1994: DS Mautz; R Labroo; Evan D Kharasch
Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry.
Journal of chromatography. B, Biomedical applications 1994;658(1):149-53.
1994: Evan D Kharasch; Kenneth E Thummel; DS Mautz; S Bosse
Clinical enflurane metabolism by cytochrome P450 2E1.
Clinical pharmacology and therapeutics 1994;55(4):434-40.
1993: Evan D Kharasch; Kenneth E Thummel
Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane.
Anesthesiology 1993;79(4):795-807.
1993: Evan D Kharasch; Kenneth E Thummel; Jill M Mhyre; J H Lillibridge
Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
Clinical pharmacology and therapeutics 1993;53(6):643-50.
1993: Evan D Kharasch; Kenneth E Thummel
Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?
Anesthesia and analgesia 1993;76(5):1033-9.
1993: Kenneth E Thummel; Evan D Kharasch; T Podoll; K Kunze
Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(2):350-7.
1992: Evan D Kharasch; R Labroo
Metabolism of ketamine stereoisomers by human liver microsomes.
Anesthesiology 1992;77(6):1201-7.
1992: Evan D Kharasch; S Herrmann; R Labroo
Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism.
Anesthesiology 1992;77(6):1208-14.
1992: Evan D Kharasch
Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation.
Anesthesia and analgesia 1992;74(4):602-4.
1991: Evan D Kharasch; H F Hill; A C Eddy
Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism.
Anesthesiology 1991;75(3):520-4.
1991: Evan D Kharasch; M Sivarajan
Aerosol propellant interference with clinical mass spectrometers.
Journal of clinical monitoring 1991;7(2):172-4.
1991: Evan D Kharasch; T Andrew Bowdle
Hypokalemia before induction of anesthesia and prevention by beta 2 adrenoceptor antagonism.
Anesthesia and analgesia 1991;72(2):216-20.
1989: John T Slattery; Teresa OSBORN; R Reynolds; Thomas F Kalhorn; Evan D Kharasch; A C Eddy
Lack of effect of cimetidine on acetaminophen disposition in humans.
Clinical pharmacology and therapeutics 1989;46(5):591-7.
1989: Evan D Kharasch; K T Yeo; M A Kenny; D W Amory
Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels.
Canadian journal of anaesthesia = Journal canadien d'anesthésie 1989;36(5):545-53.
1988: Evan D Kharasch; K T Yeo; M A Kenny; Charles W Buffington
Atrial natriuretic factor may mediate the renal effects of PEEP ventilation.
Anesthesiology 1988;69(6):862-9.
1988: G Alec Rooke; Evan D Kharasch
Left ventricular free wall rupture in acute myocardial infarction--a spectrum of severity.
Journal of cardiothoracic anesthesia 1988;2(2):218-22.